Daxing Liu

Title: Daxing Liu: Innovator in Cancer Therapeutics

Introduction

Daxing Liu is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer therapeutics, holding a total of 3 patents. His innovative work focuses on engineered liposomes and cationic polymers, which have the potential to revolutionize cancer treatment.

Latest Patents

One of Liu's latest patents is titled "Engineered liposomes as cancer-targeted therapeutics." This patent discloses liposomes that are designed to target cancer cells by conjugating ligands, such as EGFR ligands and ICAM-1 ligands, to their surfaces. The molecular ratio of these ligands is tailored to match the overexpressed proteins on the surface of targeted cancer cells. Another significant patent is "Cationic polymers as co-drugs for chemotherapeutic agents." This patent outlines a method for treating biological cells by administering a mixture of a chemotherapeutic drug and a co-drug that enhances the delivery of the drug to the cell nucleus. The co-drugs include various cationic polymers, lipids, and proteins, such as polyethyleneimine and protamine.

Career Highlights

Throughout his career, Daxing Liu has worked with notable organizations, including Children's Medical Center Corporation and The City University of New York. His experience in these institutions has allowed him to develop and refine his innovative approaches to cancer treatment.

Collaborations

Liu has collaborated with esteemed colleagues, including Debra Auguste and Marsha A Moses. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Daxing Liu is a dedicated inventor whose work in cancer-targeted therapeutics is paving the way for more effective treatments. His innovative patents and collaborations highlight his commitment to improving patient outcomes in the fight against cancer.